









Markets
/
Stocks
/
nasdaq-cldi
/

Calidi Biotherapeutics Inc

CLDI

0.862USD

+0.020+2.36%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

5.95MMarket Cap

2.66P/E TTM



Calidi Biotherapeutics Inc

0.862

+0.020+2.36%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Calidi Biotherapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Calidi Biotherapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 183 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.

Calidi Biotherapeutics Inc's Score

Industry at a Glance

Industry Ranking

183 / 392

Overall Ranking

349 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Calidi Biotherapeutics Inc Highlights

StrengthsRisks

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.

Overvalued

The company’s latest PE is 2.66, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 34.73K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.93.

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

10.000

Target Price

+4247.83%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Calidi Biotherapeutics Inc is 7.19, ranking 143 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.19

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Calidi Biotherapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Calidi Biotherapeutics Inc is 7.00, ranking 189 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 2.66, which is 62.42% below the recent high of 4.32 and 843.75% above the recent low of -19.76.

Score

Industry at a Glance

Previous score

7.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 183/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Calidi Biotherapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

10.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

10.000

Target Price

+4247.83%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Calidi Biotherapeutics Inc

CLDI

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

No price momentum score is currently available for Calidi Biotherapeutics Inc. The Biotechnology & Medical Research industry's average is 6.51.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.012

Sell

RSI(14)

25.691

Sell

STOCH(KDJ)(9,3,3)

11.698

Oversold

ATR(14)

0.076

Low Volatility

CCI(14)

-210.437

Oversold

Williams %R

91.263

Oversold

TRIX(12,20)

-1.004

Sell

StochRSI(14)

34.404

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.926

Sell

MA10

0.975

Sell

MA20

1.019

Sell

MA50

1.214

Sell

MA100

1.375

Sell

MA200

3.039

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Calidi Biotherapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.83%, representing a quarter-over-quarter decrease of 23.29%. The largest institutional shareholder is The Vanguard, holding a total of 34.73K shares, representing 0.48% of shares outstanding, with 52.67% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Lincoln Alternative Strategies LLC

730.00K

Leftwich (Scott)

146.63K

+577.97%

Schoeneck (James A)

84.51K

+788.59%

Hightower Advisors, LLC

84.96K

+753.31%

Jamir Trust

50.81K

+0.21%

The Vanguard Group, Inc.

Star Investors

34.73K

+17.93%

Kessler (Judd S)

31.08K

Geode Capital Management, L.L.C.

29.59K

+52.70%

Poma (Eric E. Ph.D.)

25.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Calidi Biotherapeutics Inc is 2.78, ranking 200 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.